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Abstract 
Bladder instillation therapy instills intravesical medication into the bladder to treat 
superficial bladder cancer.  Nursing staff, using a consistent standardized approach to bladder 
intravesical administration, can improve patient outcomes and decrease adverse events.  The 
purpose of this Doctor of Nursing Practice (DNP) project is to improve the care of superficial 
bladder cancer patients receiving intravesical bladder cancer treatments by evaluating and 
revising an existing intravesical bladder protocol to reflect current evidence-based practice.  
Nursing staff were provided with an educational program regarding bladder cancer and 
intravesical bladder treatments.  The Iowa Model of Evidence-Based Practice to Promote 
Quality Care framework was used to develop the project.  The current bladder instillation 
protocol was evaluated and revised to reflect current evidence based practice.  A nursing 
educational lecture focusing on superficial bladder cancer, risk factors, diagnosis, and 
treatment options was then developed and presented to twelve nursing staff members.  
Continuing education credits were awarded to those who attended the educational program.  
Patient education materials regarding bladder intravesical therapy also were evaluated and 
revised.  A patient educational handout for Valrubicin was developed.  Implementation of the 
revised evidence-based protocol will occur as the next step to extend the current DNP project.   
In conclusion, outcomes for patients receiving bladder instillation therapy can be 
improved by a consistent standardized approach to their care.  Nurses who are knowledgeable 
about the disease process and treatments of their patients can help to improve patient 
outcomes.  Nurses who practice utilizing evidence-based protocols will promote the highest 
level of quality and safety for their patients.  Implementation of this project will ultimately 
lead to more optimal care and improved patient outcomes.    
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Chapter I 
Introduction 
 
Nursing care is guided by nursing standards and protocols.  Nursing standards are 
important as they provide, “the basis for measuring and assuring quality” (Buss, 1993, p. 238).  
Nursing protocols define the management of patient specific care.  Protocols can be 
categorized as interdependent protocols, independent protocols, and teaching protocols 
(O’Donnell, 2005).  Evidence-based nursing care is directly related to optimal patient 
outcomes.  Standardizing care to eliminate variation among individual nurses is crucial to the 
delivery of safe, high quality care.  In order to achieve such standardization of care, protocols 
are developed to support nurses to provide evidence-based nursing care using a standardized 
approach.   
Protocols are particularly essential in the use of complex and high-risk therapies where 
multiple steps must be followed by nurses in the delivery of care.  Nursing staff must be 
oriented and trained in how to follow the steps in the protocol.  Intravesical bladder 
installation therapy is an example of such a therapy that requires use of a standardized, 
evidence-based protocol.  The protocol for bladder instillation therapy in the urology clinic 
had not been updated since 2012 to reflect current evidence-based practice.   
Therefore, the purpose of this project was to evaluate and revise the existing 
intravesical bladder protocol and provide nursing staff with an educational program regarding 
bladder cancer and intravesical bladder treatments.  This was accomplished by developing a 
program to educate nursing staff on current evidence-based practice and treatments regarding 
bladder cancer, revising the bladder cancer intravesical protocol to support consistent use of 
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the evidence-based practice, and evaluating and revising the patient education handouts to 
reflect the evidence-based practice.   
This project did not require an Institutional Review Board (IRB) review.  This project 
was a quality improvement initiative.  No human subject data collection or information was 
accessed.  As there was no human subject data collection or informational access an IRB 
review was not required. 
The Problem 
According to the National Institutes of Health (2012), a protocol is, “a detailed plan of 
a scientific or medical experiment, treatment, or procedure”.  Established protocols are 
important in the hospital environment, where there is an increased risk of infection, 
medication errors, and errors during procedures (Institute of Medicine [IOM], 2000).  The 
IOM reported in 2001 that, “….scientific knowledge about best care is not applied 
systematically or expeditiously to clinical practice” (IOM, 2001, p. 5).  However, protocols 
are often followed based on the logic that a procedure has always been done a certain way so 
no changes need to be made (Jyothi, 2012).  Evidence-based practice improves the quality of 
patient care by utilizing research to evaluate best practices (Jyothi, 2012).  Evidence-based 
practice is the translation of research findings into best clinical practice to improve healthcare 
and patient outcomes (Stevens, 2001).   
Current Practice Issues 
In the intravesical bladder instillation clinic at a large academic medical center, a 
protocol was previously developed to guide the administration of intravesical bladder cancer 
medication, but the protocol did not reflect current evidence-based nursing practice.  It is 
unclear when the original protocol was developed.  The protocol is embedded within the 
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overall chemotherapy administration protocol.  The protocol for bladder instillation therapy 
was most recently revised in December 2012 by nursing education staff who had no 
experience with intravesical bladder instillation treatment.  The protocol was revised utilizing 
evidence-based research that was standard practice for an operating room setting.  There was 
no literature utilized from an ambulatory setting.  The existing protocol did not reflect the 
current practice in the bladder instillation clinic, nor did it reflect evidence related to the 
therapy itself.  This type of gap between the established protocol versus evidence-based 
practice is important to address because it can result in less than optimal patient outcomes 
(Thompson & Kagan, 2011).   
The original orientation program was developed in 2004 by nursing staff to orient new 
nurses administering intravesical therapy.  The bladder instillation clinic was moved to a new 
location with new nursing staff in 2012, and all staff were trained using the original 2004 
orientation program.  The orientation program was then updated shortly after the move to the 
new unit in 2012 by the same nursing educator that was not involved in the administration of 
bladder intravesical therapy or the care of bladder cancer patients.   
Nursing staff currently begin orientation by reading an article entitled, Intravesical 
antineoplastic therapy following transurethral resection of bladder tumors:  Nursing 
implications from the operating room to discharge (Washburn, 2007).  New employees also 
review the chemotherapy and hazardous materials safe handling policies, observe and then 
perform one intravesical bladder instillation with each of the medications given at the 
hospital.  The orientees must then pass a written quiz on the information learned during all of 
these orientation activities.  They are then deemed competent to give bladder intravesical 
therapy independently.  
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A thorough understanding of disease processes and treatments is necessary for nurses 
to demonstrate competent technical skills and critical thought processes and to provide a high 
standard of care (Bashford & Shaffer, 2012).  Nursing care should be both safe and effective 
as an end result of these abilities.  Several organizations have published reports on the 
importance of nursing staff understanding disease process and treatments leading to an 
improvement in quality of care.  For example, the Institute of Medicine published a report 
entitled, Health Professions Education:  A Bridge to Quality (IOM, 2003).  The Quality and 
Safety Education for Nurses (QSEN) initiative was a model developed from the IOM report in 
2005.  The model established guidelines based on essential components of quality and safety 
of patient care.  The six QSEN essentials address patient centered care, teamwork and 
collaboration, evidence-based practice, quality improvement, safety, and informatics (Sims & 
Bodnar, 2012).  The QSEN reports demonstrate the link between quality patient care, nursing 
staff who have the knowledge and skill set to safely care for their patients, and improved 
patient outcomes.   
The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) 
develops national safety goals each year.  JCAHO develops ambulatory care goals that are 
specific to the ambulatory care setting.  In that specific care setting, national safety goals for 
2014 include improved safety when administering medications (The Joint Commission 
[JCAHO], 2013).  A competency based orientation program therefore gives nursing staff the 
knowledge they need to support and achieve the 2014 JCAHO safety goal, and to improve 
patient outcomes.  
 
 
BLADDER INSTILLATION THERAPY 9 
 
Role of Evidence-based Practice 
Further increasing the importance of evidence-based care with this particular patient 
population is the fact that medications instilled into the bladder to treat superficial bladder 
cancer are classified as biohazardous.  Nurses are at risk for exposure when transporting, 
administering, and disposing of biohazardous medication waste and body fluids (Hennessy & 
Dynan, 2014).  It is documented in literature that nurses exposed to hazardous medications 
have experienced adverse reproductive outcomes and increased occurrence of cancer 
(Polovich & Clark, 2012).  Because of the risk to healthcare workers when handling these 
medications, personal protective equipment (PPE) is required for administration of biotoxic 
medications (Polovich & Clark, 2012).  PPE is utilized during intravesical bladder medication 
administration in the bladder intravesical medication instillation clinic.  The PPE utilized 
follows the cancer hospital’s chemotherapy safe handling guidelines.  However, the type of 
PPE utilized was not accurately reflected in the current protocol and therefore did not 
effectively protect nurses from the danger of exposure.   
Patient educational materials are given to patients to educate them on their diagnosis 
and treatments.  Educational materials can be presented various forms of print and media.  A 
Healthy People 2020 objective looks at the concern of provider and patient communication 
clarity as well as recognizing the need for research to improve health communication 
(Ferguson & Pawlak, 2011).  Studies have shown that when patients are educated and 
involved in their care, outcomes can be improved (Arnetz et al., 2010).  Educational materials 
provide information on specific patient diagnoses, treatment options available, details on 
patient procedures, and a discussion of side effects that can be expected from treatment.  In 
the bladder intravesical instillation clinic at the cancer hospital, patient educational handouts 
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discuss specifics of treatment and side effects that may occur.  Information is given related to 
when the patient should call the clinic should complications occur.  The patient educational 
material currently distributed reflected the existing bladder intravesical protocol but not the 
current practice in the bladder instillation clinic.  Erroneous information on the current 
handouts was crossed out prior to providing handouts to patients.  Patients commented that the 
crossed out information was confusing and presented an unprofessional appearance.  There is 
a direct link between readable patient education materials and improved patient outcomes 
(Serxner, 2000), which further supported the need to update the patient educational materials 
as a part of this DNP project. 
Rationale for Protocol Changes 
The current orientation program teaches new nursing staff how to instill bladder 
medications and care for bladder cancer patients but does not follow the established and the 
existing published protocol.  The current protocol and orientation program should reflect 
current, evidence-based practice standards (Bashford & Shaffer, 2012).  This significantly 
increases the likelihood that safe and effective care is provided to patients.  The updated 
protocol also ensures that nursing personnel are adequately protected from the medication 
biohazards.   
Significance of project to nursing and health care as well as relevance to the DNP 
Essentials 
Nursing has a vested interest in ensuring that protocols are followed when performing 
procedures.  The Doctor of Nursing (DNP) degree prepares nurses to lead practice changes, 
including the development of nursing evidence-based protocols.  Nurses who are involved in 
applying and developing evidence-based research help to improve patient care practices 
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(Engvall et al., 2014).  The DNP degree focuses on use of clinical research findings and its 
implementation in the practice setting with the goal of improving patient outcomes.   
In 2006, the American Association of Colleges of Nursing (AACN) published eight 
essentials of doctorate education for advanced practice nursing.  In 2011, The National 
Organization of Nurse Practitioner Faculties (NONPF) expanded on the AACN essentials.  
The expanded DNP nurse practitioner core curriculum includes, “…critically analyzing data 
and evidence for improving advanced practice nursing, translating research and other forms of 
knowledge to improve practice processes and outcomes, and developing new practice 
approaches based on the integration of research, theory, and practice knowledge”  (The 
National Organization of Nurse Practitioner Faculties [NONPF], 2012, para. 5).   
This DNP project addressed several of the DNP essentials.  These Essentials included 
the DNP essential of scientific underpinnings for practice, organizational and systems 
leadership for quality improvement and systems thinking, interprofessional collaboration for 
improving patient and population health outcomes, and advanced nursing practice.  Essential 
I, for this scholarly project, is Scientific Underpinnings for Practice.  This essential focused on 
utilizing knowledge of the sciences to:  
1.  Critically analyze data and evidence for improving advanced nursing practice. 
2. Integrate knowledge from the humanities and sciences within the context of 
nursing science. 
3. Translate research and other forms of knowledge to improve practice processes 
and outcomes. 
BLADDER INSTILLATION THERAPY 12 
 
4.  Develop new practice approaches based on the integration of research, theory, and 
practice knowledge (American Association of Colleges of Nursing [AACN], 
2006). 
This Essential was relevant to this scholarly project as it focused on analyzing the literature 
for instillation of bladder intravesical therapy medications, analyzing the current bladder 
intravesical therapy protocol, and revising the bladder intravesical therapy protocol in order to 
reflect the most current evidence-based literature to improve patient outcomes.  This protocol 
revision focused on the current evidence, translated research and knowledge into practice, 
updated practice processes, and improved patient outcomes.  Improving the practice process is 
important to nursing as it improves nursing process, which improves patient outcomes 
(AACN, 2006). 
Essential II is Organizational and Systems Leadership for Quality Improvement and 
Systems Thinking that focused on quality improvement working within organizations by 
focusing on the needs of a population (AACN, 2006).  This Essential was relevant to this 
project by establishing a protocol that will improve quality of patient care for bladder cancer 
patients receiving intravesical bladder cancer treatments, as well as improving staff 
competence and compliance in administering this protocol.  Ensuring that the nursing staff is 
competent is important to ensuring patient safety and is important to upholding excellence in 
nursing standards.  
Essential VI is Interprofessional Collaboration for Improving Patient and Population 
Health Outcomes.  This Essential was relevant to this scholarly project as it focused on: 
1. Employing effective communication and collaborative skills in the development 
and implementation of practice models, peer review, practice guidelines, health 
BLADDER INSTILLATION THERAPY 13 
 
policy, standards of care, and/or other scholarly products. 
2.  Leading interprofessional teams in the analysis of complex practice and 
organizational issues. 
3. Employing consultative and leadership skills with intraprofessional and 
interprofessional teams to create change in health care and complex healthcare 
delivery systems (AACN, 2006).   
This Essential was relevant for the project by evaluating and revising a patient 
protocol to reflect evidence-based practice and updating the patient educational handouts to 
reflect evidence-based practice.  By updating the patient protocol and patient educational 
handouts, change in the healthcare system is created allowing for improved patient care.  
Quality improvement is important to improve the quality of clinical practice.  Quality 
improvement and the improvement of clinical practice is important for nursing as a 
profession.   
The final relevant Essential is Essential VIII:  Advanced Nursing Practice.  Essential 
VIII focuses on: 
1.  Design, implement, and evaluate therapeutic interventions based on nursing 
science and other sciences. 
2. Develop and sustain therapeutic relationships and partnerships with patients 
(individual, family, or group) and other professionals to facilitate optimal care 
and patient outcomes. 
3. Demonstrate advanced levels of clinical judgment, systems thinking, and 
accountability in designing, delivering, and evaluating evidence-based care to 
improve patient outcomes. 
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Advanced Practice Nurses assists in the education and training of nursing staff.  This 
Essential was relevant as an educational program and updated orientation program was 
developed for the nursing staff.  Evaluating and updating the orientation program increased 
the staff knowledge.  These changes increased the competency of the nursing staff.  This 
project developed and helped to sustain the partnership with the nurse practitioner and the 
nursing staff.  It provided for optimal care for the patients and worked to improve patient 
outcomes.  This Essential is important to the nursing staff as it improves competency in 
practice and supports quality and improvement initiatives.  
DNP Project Objectives 
1.  The current bladder instillation protocol will be updated to reflect evidence-based 
practice to improve patient outcomes.  A standardized and consistent approach for 
instillation of bladder medications for treatment of superficial bladder cancer will 
be developed with evidence-based standards as the foundation.   
2. Nursing knowledge will be increased related to bladder cancer and treatment 
options by revising and implementing an orientation program.  An educational 
program will be developed to instruct nursing staff on bladder cancer and its 
causes, pathophysiology, and treatments. 
3. Patient educational handouts will be evaluated and revised to reflect current 
practices, with the expectation that patients who receive accurate and evidence 
based instructions will be better supported to engage in effective self-care and 
benefit from improved outcomes.   
Patient safety is vitally important to nursing and healthcare providers.  The Hippocratic oath 
states to do no harm (Dinakar & Simon, 2006).  Evidence-based practice and standardized 
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protocols help nursing staff to provide safe care and provide for better patient outcomes.  The 
goal of this project was to update and revise the bladder instillation protocol, develop a 
nursing educational program to increase nursing knowledge related to bladder cancer and its 
treatments as part of an updated nursing orientation program, and update patient educational 
handouts to increase patient knowledge of the treatments they will be receiving.  A literature 
review was completed to explore bladder cancer, instillation of bladder cancer medications, 
and safe handling of those medications to assist in developing a protocol and an educational 
program for nursing staff to ensure safe, evidence-based care.    
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Chapter II 
Literature Review 
 
Evidence-based practice for the care of ambulatory urology oncology patients is 
developed with research to improve care and patient outcomes.  Evidence-based practice 
improves the quality of patient care (Dontje, 2007).  An initial search of the literature was 
conducted to evaluate the evidence relating to bladder cancer, biohazardous agents, safety and 
handling of biohazardous agents, and nursing orientation and patient safety.   
Bladder Cancer 
Bladder cancer is a urological cancer that affects individuals all across the United 
States (US) and the world.  Bladder cancer is the seventh most common malignancy in men 
and 17th most common in women.  Bladder cancer patients are treated by general urologists or 
urologic oncology specialists.  Treatments are specific to the cell type of cancer and differ 
according to whether the patient has superficial bladder cancer or muscle-invasive bladder 
cancer.  Superficial bladder cancer is often treated with a transurethral resection of bladder 
tumor (TURBT), followed by intravesical medication instillation into the bladder.   
Intravesical therapy is completed in the outpatient clinic setting.  At this cancer 
hospital, bladder cancer patients receive their intravesical therapy treatment in the certified 
nurse practitioner (CNP) intravesical therapy clinic.  Bladder cancer instillation therapy has 
been given at the cancer hospital urology clinic since the 1980s and in the current clinic 
location since November 2012.  The clinic is managed by the CNP and staffed with two to 
three nurses and a patient care associate.  Nursing staff need to be well versed on the 
treatments that they are administering, the side effects of those treatments, and side effects 
that can require revisions to the treatment being given.  A protocol should be in place to guide 
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administration of intravesical bladder therapy (Mellinger, Skinker, Sears, Gardner, & Shult, 
2010). 
Bladder cancer patients can typically present with one or several complaints, including 
gross painless hematuria or microhematuria noted on urinalysis (Jones & Larchian, 2012).  
Patients will often see their primary care physician first.  A urine culture and urinalysis are 
obtained, commonly revealing a negative culture.  Primary care providers should then refer 
patients to a urologist to evaluate the hematuria.    
Subsequent evaluation typically includes a cystoscopy to identify any abnormalities 
within the patient’s bladder.  A cystoscopy is a procedure in which the urologist inserts a 
telescope (cystoscope) with a small camera attached into the bladder.  The urologist is able to 
visualize the inside of the bladder for the presence of any tumors or abnormalities.  A 
transurethral resection of the bladder tumor is then performed in the operating room (OR) if a 
bladder mass is identified (Jones & Larchian, 2012).  Depending on the cell type of bladder 
cancer identified, as well as depth of tumor invasion, staging studies, and other pathologic 
variables, a decision is made on what type of treatment is needed.   
Superficial bladder cancer, also called non-invasive bladder cancer, is further 
categorized by stage.  Bladder cancer staging is the categorization of cancer cell 
aggressiveness and extent of cancer spread.  There are two types of staging – clinical and 
pathological staging.  Clinical staging is the provider’s assessment of how far the cancer has 
spread based on exam, laboratory studies, and imaging studies (American Cancer Society, 
2015).  Pathological staging is based on examination of the cancer cells underneath the 
microscope by a pathologist who determines aggressiveness of the cells and the extent of 
invasion (Urology Care Foundation, 2014).  Pathological bladder cancer staging is reported as 
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tumor staging also known as T staging (Urology Care Foundation, 2014).  Pathological stage 
Ta is the most common type of superficial bladder cancer (Washington University 
Department of Surgery, 2011).  The tumor looks like a cauliflower configuration in the 
bladder and does not grow or invade into other layers in the bladder.  These tumors are treated 
with TURBT and surveillance or alternately with TURBT and bladder instillation therapy to 
reduce recurrence risk.   
Carcinoma in situ (CIS) is another form of superficial bladder cancer.  It is seen as a 
red, velvety patch in the bladder that develops on the surface wall of the bladder.  It is a flat, 
but high grade, non-invasive cancer.  It can develop into muscle invasive disease if left 
untreated.  T1 stage bladder cancers have extended through lamina propria.  The lamina 
propria is the layer of the bladder under the epithelium or mucosa, separating the bladder 
lining from the deeper muscle layers.  The tumors may, if left untreated, develop the potential 
to invade into the muscularis propria consistent with muscle-invasive disease.   
Muscle invasive bladder cancers are not typically fully controlled by transurethral 
resection and often require radical cystectomy or chemotherapy and radiation therapy for 
definitive treatment.  For patients with superficial disease or patients with T1 disease who are 
selected for bladder instillation therapy, weekly sessions of instillation are undertaken.  BCG 
is typically six weekly instillations.  Maintenance treatments have been shown to decrease risk 
of recurrence in comparison to induction therapy alone (Lamm, McGee, & Hale, 2005).  This 
is typically given for three weekly instillations.   
Intravesical bladder cancer instillation is the instillation of medication directly into the 
bladder to affect the cells lining the bladder (American Cancer Society, 2014), and is a current 
standard of treatment for these patients.  A number of different medications can be instilled 
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into the bladder for cancer treatment.  Evidence shows that BCG is the most effective 
intravesical immunotherapy for treating early-stage bladder cancer (American Cancer Society, 
2014).  It is thought that BCG works by stimulating the body’s own immune system, thereby 
stimulating an immune reaction to the bladder cancer cells as well.  Treatment is started 
approximately four weeks after the patient’s TURBT and is given weekly for a total of six 
weeks.  An induction course of BCG is the initial six-week course that a patient is given for 
treatment.  Maintenance doses can be given every three to six months for three weeks to 
prevent recurrence.   
Chemotherapy agents that are given IV can also be given intravesically into the 
bladder for treatment.  Chemotherapy agents used for this type of treatment include 
Mitomycin C (MMC), Valrubicin (Valstar), Doxorubicin, and Thiotepa.  MMC is the agent 
that is more commonly used over the other agents.  MMC is often instilled into the bladder 
directly after a TURB while the patient is still in the OR.  It then can also be instilled into the 
bladder weekly for six consecutive weeks.  Valrubicin (Valstar) is another chemotherapy 
agent that can be utilized weekly for six consecutive weeks.  Valrubicin was approved by the 
Federal Drug Administration (FDA) for patients that have BCG resistant CIS and are not 
candidates for radical cystectomy (Cookson et al., 2014).   
Intravesical bladder medications can cause side effects when instilled into the bladder.  
The medications can cause irritative voiding symptoms of urinary frequency, urgency, and 
dysuria.  BCG can also have immunology side effects including fever, chills, flu like 
symptoms, and joint aches.  The patients fill out a Quantitative Symptom Score Sheet (QSS) 
every day during treatment starting with the day of treatment.  Patient treatment decisions are 
made based on the side effects the patients are having.   
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Table 2: Side effects of treatment and estimated probabilities of occurrence 
Intravesical Agent 
Side Effects BCG Mitomycin C Thiotepa Doxorubicin 
Frequent urination 63% 42% 11% 27% 
Painful urination 75% 35% 30% 20% 
Flu-like symptoms 24% 20% 11% 7% 
Fever or chills 27% 3% 4% 4% 
Systemic infections 4% Not available 0.3% Not available 
Skin rash 6% 13% 2% 2% 
Suppression of bone 
marrow activity 
1% 2% 13% 0.8% 
(American Urological Association [AUA], 2014) 
Monitoring of patient side effects is very important, as treatment decisions are made based on 
how the patient is tolerating the therapy.  The medications instilled into the patient’s bladder 
for treatment are considered biohazardous and need to be handled in a way that minimizes 
effects to the patients and limits exposure for the staff.  The therapy must be administered 
accurately, safely, and consistently to promote quality care.     
Biohazardous Agents 
BCG is a live culture preparation of the Bacillus of Calmette and Guerin strain of 
Mycobacterium bovis (Merck & Co, 2009).  Currently, this hospital uses TICE® BCG, which 
is manufactured by Merck.  According to Merck, (2009), BCG contains live mycobacteria and 
should be prepared and handled using aseptic technique as BCG infections have been reported 
in health care workers preparing BCG for administration.  Merck (2009) further recommends 
that TICE® BCG should be handled and disposed of as a biohazardous substance.  The 
nursing staff currently follows the hazardous drugs safe handling policy for handling of the 
BCG.  Instillation of the BCG, including handling and disposing of the materials, follows a 
protocol that was developed in December 2012 that has not been updated since that time.    
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Another agent used in the treatment of these patients is Mitomycin C (MMC).  
Mitomycin C is an antineoplastic agent and is classified as an antitumor antibiotic.  It acts as 
an alkylating agent stopping cells from making DNA, which results in cell death.  
Biohazardous medications and should be administered and disposed of in accordance with 
practices that protect the health care worker (Polovich, 2004).  The nurses in the bladder 
instillation clinic should follow the safe handling practices outlined in the hazardous drugs 
safe handling policy of this cancer hospital.  The most current instillation protocol for 
Mitomycin C, which includes handling and disposing of supplies, was developed in December 
2012 and had not been updated since that time. 
The use of Interferon acts as a glycoprotein that mediates a host’s immune system.  
Interferon increases antibody responsiveness and stimulates killer cells (Brassell & Kamat, 
2006).  Interferon alpha 2b is sometimes used in combination with BCG and can be highly 
effective in the treatment of superficial bladder cancer (Lamm et al., 2005).  Combination 
therapy is given for a 6-week induction course.  Interferon A should be handled by nursing 
staff following the Cancer Hospital’s safe handling policy of biohazard agents.  There is an 
older protocol for instillation of BCG instillation but there is no protocol for instillation of 
BCG in combination with Interferon A.  
Another agent that may be used is Valrubicin, an anthracycline antibiotic.  It prevents 
protein synthesis by binding DNP base pairs and inhibits topoisomerase II (Brassell & Kamat, 
2006).  Valrubicin is given for patients who have failed BCG therapy and are not good 
surgical candidates for cystectomy.  Valrubicin is a biohazardous agent and should be handled 
and discarded following appropriate protocols.  The nursing staff are instructed to follow the 
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cancer hospital’s safe handling guidelines of biohazard agents for handling and disposal, but 
there is a need for a separate defined protocol for intravesical instillation of Valrubicin.   
Safety in Handling and Administration of Biohazardous Agents 
Safe administration and handling are important to protect health care workers from 
exposure to biohazardous agents.  Hazardous drugs are categorized by exhibiting specific 
characteristics.  Drugs exhibiting one or more of the following effects are classified as 
hazardous:  carcinogenicity, teratogenicity, genotoxicity, reproductive toxicity, or organ 
toxicity at low doses (American Society of Health System Pharmacists, 2006).  Health care 
providers can be exposed to hazardous agents during preparation, handling, administration, 
and disposal of the agents.  Such exposure to biohazardous agents has been linked to long 
term and acute health effects including reproductive effects and increased incidence of cancer 
(Polovich & Martin, 2011).  For example, leukemia and other cancers were linked to several 
chemotherapy agents in the 1970’s (Thomas & McDiarmid, 2006).   
Cytotoxic findings led to the consideration of exposure causing risk of cancer to the 
healthcare workers that handled them (Polovich, 2004).  A controlled study was done that 
noted toxins in the urine of patients and healthcare workers that were exposed to 
chemotherapy drugs (National Institute for Occupational Safety and Health [NIOSH], 2004).  
Beginning in the 1980’s, guidelines were published with recommendations to reduce the risk 
of exposure to healthcare workers when handling biohazards drugs.   
The first such guidelines came from the American Society of Hospital Pharmacists 
(Polovich & Martin, 2011).  The organization published guidelines in 1985 detailing safe 
handling precautions for healthcare workers to decrease exposure to potentially unsafe 
medications (ASHP, 1985).  In 1986, the Occupational Safety and Health Administration 
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(OSHA) developed guidelines addressing the issue of safe handling of biohazardous drugs.  In 
1988, the Oncology Nursing Society published recommendations for safe handling of 
biohazardous drugs (Polovich, 2005).     
The Occupational Safety and Health Act of 1970 established the National Institute for 
Occupational Safety and Health (NIOSH) (Centers for Disease Control [CDC], 2013).  
NIOSH is a federal agency that utilizes evidence-based research to make recommendations 
for worker safety.  NIOSH collaborated with the Occupational Safety and Health 
Administration (OSHA) and is part of the CDC (CDC, 2013).  NIOSH supports research to 
improve employee safety in the workplace (CDC, 2013).   
NIOSH publishes recommendations focused on health workers’ occupational hazards 
in handling cytotoxic drugs (National Institute for Occupational Safety and Health [NIOSH], 
2004).  NIOSH continues to update these guidelines to protect healthcare workers from 
occupational exposure.  Since the NIOSH alert was published in 2004, the organization has 
updated their list of biohazardous drugs in 2010, 2012, and 2014.  BCG, Mitomycin C, and 
Valrubicin are included in the NIOSH list of biohazardous drugs, and such updates must be 
included in the processes and practices related to their implementation.   
NIOSH recently published a new Occupational Exposure to Antineoplastic and Other 
Hazardous Drugs in Health Care (NIOSH, 2014).  The recommendations were given to limit 
the exposure during hazardous drug preparation and handling.  Within the report, NIOSH 
provided a list of biohazardous drugs that healthcare workers should take precautions when 
handling.  The purpose of this report was to increase awareness of healthcare workers and 
their agencies in the hazards related to handling of biotoxic medications (Polovich & Martin, 
2011).   
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Nursing Orientation and Patient Safety 
Nursing professionals are responsible for having the knowledge to provide safe care to 
patients.  Nurses must ensure that safe practices are followed to decrease the risk of harm to 
patients as well as to themselves.  This is particularly true in the administration of certain 
therapies that can be toxic, such as chemotherapeutic agents.  Orientation and education are 
both necessary to provide training to communicate appropriate protocol and procedures to 
nursing staff (Mellinger, Skinker, Sears, Gardner, & Shult, 2010).   
In summary, bladder instillation medications are biohazardous, and patients and their 
nurses can be seriously harmed if there is a lack of compliance with handling procedures 
(NIOSH, 2014).  Proper protocols should be followed to ensure safety of both the nursing 
staff and patients during administration (NIOSH, 2014).  Without proper training and 
evidence based protocols to guide the administration, harm can come to patients in the 
development of infections, and to nurses in the development of cancers and other detrimental 
health effects (Polovich & Martin, 2011).  The outpatient clinic has the responsibility for 
ensuring the safety of the nursing staff and patients. 
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Chapter III 
Methods 
Project Design 
Nursing protocols allow for application of nursing knowledge in a standardized 
approach in order to improve patient outcomes.  This project was guided by the Iowa Model 
of Evidence-Based Practice to Promote Quality Care theoretical model (Titler et al., 2001).  
This project utilized a quality improvement design to improve clinical practice.  The setting 
was in the intravesical bladder instillation clinic at a large Midwestern Cancer Hospital.  The 
project evaluated and revised the current Intravesical Bladder Installation Protocol (see 
Appendix A).  Development of the protocol followed guidelines set by this large urban 
Midwestern Cancer Hospital.  It is anticipated that the protocol will be submitted for approval 
to the institution’s Policy and Procedure Committee after the completion of this student’s 
DNP clinical immersion experience.  
The orientation process for new nursing staff was also evaluated and revised to 
provide updated and evidence based knowledge to those nurses regarding intravesical bladder 
instillation therapy.  A formal presentation was presented to educate nurses on bladder cancer 
and the treatments available.  The revised orientation program was designed as part of this 
DNP project and will be implemented after completion of the DNP program.  The current 
patient educational handout (see Appendix B) was also evaluated and revised to reflect the 
change in nursing protocol.   
Sample 
The sample for this project was the nursing staff who work in the bladder intravesical 
instillation clinic.  The nursing staff is currently comprised of Registered Nurses (RNs) who 
are assigned to that clinic.  The RNs currently working in the clinic have been on staff there, 
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on average, for the past year, so represent a relatively new nursing employee group for whom 
the updated education could be especially beneficial.  There are patient care associates who 
work in the clinic but they were not a focus of this project as they are not directly involved in 
implementing bladder installation therapy.   
Process 
In order to develop a consistent approach to bladder instillation therapy to improve 
patient outcomes, a process plan was developed.  An outline of steps to the project was 
developed to ensure that all facets of the plan were addressed.  This plan included 
development of an evidence-based process and protocol for the administration of bladder 
instillation therapy, and detailing the standard nursing care before, during and after the 
procedure.   
Step One: 
Intravesical bladder cancer instillation protocols are currently embedded in the 
chemotherapy administration protocol within the institution in which this DNP project was 
implemented.  The first step evaluated the current protocol and compared it to the current 
practice in the bladder intravesical therapy instillation clinic.  Differences between the 
protocol and actual practice, including safety practices, were evaluated.  The protocol was 
then updated to reflect current evidence-based practice and must be submitted and approved 
by the cancer hospital prior to implementation.  The implementation process will be initiated 
after completion of the DNP program.  Future steps will include completion of the approval 
process and implementation of the protocol changes in the bladder intravesical therapy clinic.  
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Step Two: 
The orientation program for the nursing staff in the bladder intravesical instillation 
clinic was evaluated and compared to the revised protocol.  Updates were made to improve 
nursing knowledge of bladder cancer and intravesical treatment options for superficial bladder 
cancer.  The orientation process was updated to reflect the new protocol.  An educational 
program was developed and presented to the nursing staff to educate them on superficial 
bladder cancer and available treatment options.  Information was not included regarding the 
revised protocol, as it is not yet approved by nursing administration.  Education regarding the 
revised protocol will be presented later after the protocol has been approved by the protocol 
committee.  Continuing education credits were awarded to staff that attend the program, and it 
will become a component of the annual competency testing that is mandatory for all nurses on 
the unit. 
Step Three: 
The current patient education packet was evaluated and compared to the new protocol.  
Updates were made to revise the educational material to reflect the newly revised intravesical 
protocol.  The revised patient educational material was submitted to the patient education 
department at the cancer hospital for approval with the goal of implementation after 
completion of this project. 
Instruments 
A nursing evaluation form was utilized to measure response to the nursing educational 
program that will be presented to nursing staff.  The evaluation form will measure the quality 
of the educational program, knowledge gained from the educational program, and overall 
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response to the educational program.  The evaluation form will be utilized to evaluate any 
future needs/improvements to the course in the future. 
Data Analysis Plan 
This project will make a difference in the clinical practice in the bladder instillation 
clinic.  Standardized information provided to all new nurses as well as current nursing staff 
ensures that the rationale for care of these patients is at the foundation of their preparation for 
work in this clinic.  Annual competency testing will measure retention of knowledge about the 
updated protocol in the form of a written quiz. 
  
BLADDER INSTILLATION THERAPY 29 
 
Chapter IV 
Findings 
 
Results 
The purpose of this project was to evaluate and revise the existing intravesical therapy 
protocol for bladder cancer and to provide nursing staff with an education program regarding 
bladder cancer and intravesical bladder treatments.  The intravesical therapy protocol was 
evaluated and found to have multiple discrepancies between the protocol and actual nursing 
practice.  Discrepancies noted ranged from the type of urethral catheter used, to how the 
procedure is done, to post-procedure patient education instructions.  The changes were made 
to align the protocol with evidence-based practice standards.  
Intravesicular Bladder Instillation Protocol 
The current bladder intravesicular therapy protocol is embedded in the 
Chemotherapeutic/Biotheraputic Agents protocol.  When a search for this protocol is 
attempted under search terms specific to intravesical instillation therapy, the protocol is not 
found due to the protocol being a part of the chemotherapy infusion protocol.  Unless one 
specifically knows that bladder instillation therapy is embedded into the chemotherapy 
administration protocol, it cannot be easily accessed.  The protocol is divided into the 
following topics:  supplies, patient education, procedure specific assessment and 
interventions, and post procedure complication signs and symptoms.  Implementations are 
listed under each topic and detail the procedure.  The current protocol was based on published 
findings related to bladder intravesical therapy that is administered in the operating room and 
not in the ambulatory setting.   
In a review of the literature, it was found that there is little research pertaining to this 
therapy in the ambulatory setting.  Protocols from other organizations were reviewed from 
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both within and outside of the United States.  Stamford Hospital developed a protocol 
outlining intravesical instillation and administration of both BCG and MMC (Thompson, 
2011).  In their protocol, it is noted that it is important to provide the proper safety protection 
for personnel administering the medications (Thompson, 2011).  In a review of Western 
Australia’s bladder instillation protocol, the authors noted that any practitioner giving 
intravesical therapy needs appropriate training and assessment (Washington Cancer and 
Palliative Care Network, 2010).  After a thorough review of the literature as well as current 
national standards of practice for this procedure, the following changes were made to the 
intravesical therapy for bladder cancer protocol (see Appendix A): 
• Supplies: 
 “Foley catheter kit” changed to:  urethral catheter kit. 
 “14 or 16 french-foley catheter” changed to:  Coude or red rubber catheter. 
 “Biohazard bag” changed to:  Biohazard trash bag (Yellow or Red depending 
on medication instilled) (The Ohio State University Wexner Medical Center 
[OSUMC], 2014). 
• Patient Education: 
 “Explain to patient – the procedure will be done once per week for six weeks in 
a row” changed to:  Explain to patient – the procedure will be done once per 
week for either three or six weeks in a row (Lamm et al., 2000). 
 “Explain to patient not to urinate for 2 hours after the procedure” changed to: 
Explain to patient not to urinate for 2 hours after the procedure.  (Intravesical 
medication needs to remain in the bladder for 2 hours and not more than 3 
hours) (Farah, Ghanem, & Amr, 2014). 
BLADDER INSTILLATION THERAPY 31 
 
 “1 cup of household bleach should be added to the toilet and let it stand for 15 
minutes prior to flushing the toilet” changed to:  one cup of household bleach 
should be added to the toilet and let it stand for 15 minutes prior to flushing 
the toilet twice with the toilet lid down (Merck & Co, 2009). 
 “Instruct patient to call the hospital operator and ask for the resident on call or 
their physician or go to the ER” changed to: If patient develops a fever over 
101.5 seek medical attention if does not resolve with Tylenol or NSAIDs 
(Merck & Co, 2009).   
 “PPE (mask, gloves and gown) will be worn from start to finish of procedure” 
changed to: PPE (mask, gloves {double gloved with chemotherapy and sterile 
gloves}, goggles, and gown) will be worn from start to finish of procedure 
(Polovich, 2004). 
 “Mitomycin C:  Instill medicine into Foley catheter and allow contents to go 
into bladder by gravity.  Deflate Foley balloon and remove Foley catheter” 
changed to: Instill medicine into catheter by slow pushing the medication into 
catheter with a toomey catheter tip syringe.   
 “BCG:  Squeeze tubing chamber to allow medicine to drain part way into the 
chamber” changed to:  squeeze bottle to start flow of medicine (The Ohio State 
University James Cancer Hospital [The James], 2012).  
Changes to departmental policies and procedures need to go through several steps 
prior to approval.  First, the changes are identified by an individual or group.  The proposed 
changes are noted and then must be submitted and authorized by the department director and 
administrator.  The department director ensures that implementation, communication and 
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enforcement of the policies and procedures occurs (The Ohio State University Wexner 
Medical Center [OSUMC], 1993).   
For the newly revised bladder intravesical instillation protocol, the proposed changes 
have been identified and are awaiting submission to the department director and administrator.  
The changes to the bladder intravesical installation protocol led to the need to update the 
patient education handouts.  
Patient Education 
 BCG and Mitomycin C each have a patient education handout.  The Mitomycin C 
patient education handout was last updated on May 20, 2011.  The BCG patient education 
handout was last updated on April 3, 2013.  There is no patient education handout for 
Valrubicin.   
BCG 
The BCG patient education handout is entitled, “BCG Therapy – Intravesical 
Treatment for Bladder Cancer”.  There were minimal changes to this document.  A sentence 
was added stating that BCG can alternately be given once a week for three weeks if receiving 
maintenance therapy.  A revision was made to the following statement: “If you have a 
temperature greater than 101 degrees Fahrenheit, go to the nearest Emergency Room,” which 
then became  “If you have a temperature greater than 101.5 degrees seek medical treatment” 
(Merck & Co, 2009) (see Appendix B).   
Mitomycin C 
The Mitomycin C patient education handout is entitled, “Mitomycin-C Therapy 
Intravesical Treatment for Bladder Cancer”.  This document has not been updated in almost 
four years.  The Mitomycin C patient education document had more extensive changes.  The 
BLADDER INSTILLATION THERAPY 33 
 
handout noted that for male patients, “A clamp will be placed on your penis to make sure the 
Lidocaine does not drain out.  The clamp will be removed after 10 minutes” (OSUMC, 2011, 
para. 12).  This sentence was deleted as this practice is not routinely done in the clinic.    
Additional information was added to paragraph 15, to read, “After Mitomycin-C is 
given, the catheter is removed.  The Mitomycin-C will remain in the bladder” (OSUMC, 
2011, para. 15).  An additional sentence was added as follows:  “You will need to lie flat for 
15 minutes after the procedure.  After lying flat for 15 minutes, you will be able to get up, 
wash your genital area, and get dressed” (Lamm, McGee, & Hale, 2005).   
The following sentence was changed from, “write down how long you held the 
medicine in your bladder” to “write down how long you held the medicine in your bladder on 
the bottom of your Quantitative Symptom Score Sheet”.  The following two sentences were 
deleted – “Do not flush the toilet when you finish urinating” and  “Before you flush, you must 
first pour one cup of bleach into the toilet, and let it stand for 15 minutes.  You may then flush 
the toilet”.  The following sentence was added instead:  “Flush the toilet twice with the lid 
down” (OSUMC, 2014).   
A notation was also added that the medication can cause a blue tint to urine that the 
patient may notice when urinating and the color change is normal.  The last sentence of the 
document was changed from “If you have a temperature greater than 101 degrees go to the 
nearest Emergency Room” to “If you have a temperature greater than 101.5 seek medical 
attention” (See Appendix C).   
Valrubicin 
As a part of this DNP project, a patient education handout entitled, “Valrubicin 
Therapy Intravesical Treatment for Bladder Cancer” was developed.  Valrubicin is a 
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chemotherapy with similar instillation procedure as well as similar side effects and 
precautions.  The Mitomycin C patient education handout was used as a template.  References 
to Mitomycin C were changed to Valrubicin.  A notation was made that the Valrubicin can 
cause a red tint to urine as the medication is red in color and that the color change to urine is 
normal.  The patient education materials regarding Valrubicin have been submitted to the 
patient education department for approval.  After updating the bladder instillation protocol 
and patient education materials, it was determined that an education program and an update to 
the nursing orientation process were both needed to ensure that nursing staff was 
knowledgeable about bladder cancer and bladder instillation therapy.  Imparting these 
evidence-based practice changes to staff was essential to ensuring the safety of both staff and 
their patients as well as improving patient outcomes (See Appendix D). 
Nursing Education Program 
On February 3, 2015, a program entitled “Urological Surgical Oncology: What 
Registered Nurses Should Know” was presented to the Urology Clinic staff.  The program 
was an overview of the urological cancers that the nursing staff encounters in their care of 
their clinic patients.  Included in that presentation was a half-hour session focused specifically 
on bladder cancer discussing diagnosis, types of bladder cancer, treatments for superficial 
bladder cancer, and safety considerations.  Twelve RNs attended the education program.  One 
contact hour of continuing education credit (CE), approved by the Ohio Board of Nursing, 
was provided to the RNs who attended.   
Objectives for the program were to discuss intravesical bladder cancer treatments and 
safety implications, explain the side effects of intravesical bladder cancer treatments, and 
discuss potential complications of intravesical bladder cancer treatments.  The program was a 
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lecture utilizing PowerPoint slides, and began with an introduction to bladder cancer.  
Statistics and risk factors related to the bladder cancer population were included, as well as 
the various types of bladder cancer and images of the tumors associated.  Pathological staging 
was discussed including what determines if bladder cancer is superficial or muscle invasive.  
Procedures and treatment options were presented, with a focus on intravesical therapy. The 
program then moved to discussing the specifics of BCG, Mitomycin C, and Valrubicin 
including history of development, indications, side effects of medication, complications, and 
rare complications.  The education program ended with a discussion of the bladder instillation 
protocol that included specifics on how the procedure is done and safety considerations for 
nursing staff.    
The nursing staff was provided with a participant evaluation form immediately 
following the education program (see Appendix E).  The education program was rated on 
faculty’s expertise facilitating learning, faculty demonstrating respect for the learner’s needs 
(question/opinions), objectives relating to purpose/goals, and the effectiveness of faculty 
teaching methods (slides, handouts, videos, etc.).   
The evaluation form also rated the following:  education activity positively impacts 
care and/or outcomes for patients, did the program support or enhance professional 
development, list one thing you plan to do differently at work as a result of attending, list 
other learning needs, and were the objectives of discussing intravesical bladder cancer 
treatments, safety implications, potential complications, and explaining side effects met.  The 
last question evaluated whether the purpose of the activity was met.  Twelve evaluation forms 
were returned.  The responses to the program were overwhelmingly positive.  Each of the four 
evaluation statement were rated by a numerical scale with 5 = strongly agrees, 4 = agrees, 3 = 
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neutral, 2 = disagree, and 1 = strongly disagrees.  For each of the four evaluation statements 
all twelve participants rated the faculty at a 5 for facilitating learning, demonstrating respect 
for needs, objectives related to purpose/goals, and teaching methods.  The education activity 
positively impacting care question was answered either yes or no.  All twelve respondents 
indicated that the education activity would positively impact the care of their patients.  Some 
of the respondent’s comments for this question included the following:  
• More knowledgeable, able to be more supportive of patients 
• More in depth information and understanding of care 
• My daily work involves the patient population so I am now better informed to take 
care of this patient population 
• Absolutely!  The more informative our front line staff are in giving BCG helps to 
ensure patients have positive outcomes throughout the cancer treatments 
The next survey item assessed whether or not the program enhanced the staff’s 
professional development.  All twelve respondents answered yes, indicating that the program 
did enhance their professional development.  The next question asked what the responder 
planned to do differently as a result of the program and responses stated that they now had 
increased knowledge that would allow them to provide better education for patients, they 
would continue nursing educational activities, and that they would be more informed to safely 
care for BCG patients.  The next response addressed whether each of the objectives listed at 
the beginning of the program were addressed and were answered either yes or no.  All twelve 
respondents answered that each of the objectives were met.   
The next survey item asked if the purpose of the activity was met, with all respondents 
answering yes.  The final question addressed if there was any bias in the program and all 
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respondents answered no.  The overall feedback from the program was overwhelmingly 
positive and respondents indicated that their knowledge of bladder cancer, intravesical bladder 
cancer treatment, and safety considerations were increased as a result of the program.  In 
addition to the education program, changes to the nursing orientation program were 
developed. 
Nursing Orientation to the Bladder Intravesical Instillation Clinic 
As newly hired nurses are oriented to the Bladder Intravesical Instillation Clinic, they 
are informed about the evidence-based protocols with which they will be working.  Such 
information ensures quality and safe care to patients, as well as protection from chemotherapy 
exposure.  The Nursing Orientation Program in the bladder instillation clinic had been in place 
for years and reflected outdated and inaccurate information.  Revisions to the protocol for 
intravesical therapy for bladder cancer, and updates to patient education materials revealed 
that the nurse orientation process needed updating.  The orientation process was evaluated and 
compared to current evidence, current practice, and protocol revisions.   
Competency:  Intravesicular Bladder Administration 
When nursing staff begin orientation to the intravesical therapy clinic, they are given a 
notebook to review that has a variety of materials related to the instillation of BCG, 
Mitomycin C, and Valrubicin.  A completed ‘orientation skills’ checklist is required before 
newly hired staff independently administer intravesical bladder therapy.  This list was updated 
in November of 2012 and is entitled “Competency:  Intravesicular Chemotherapy BCG (The 
Ohio State University James Cancer Hospital, 2012).   
The list contained two objectives as follows:  1.) RN will demonstrate safe 
administration of intravesicular chemotherapy according to policy and procedure, and 2.) RN 
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will describe patient education process, resources, and documentation (The Ohio State 
University James Cancer Hospital, 2012).  The skills check off list was then divided into 
sections, including review, patient education, and administration.  The nursing review section 
required various nursing journal readings while the patient education section required review 
of current patient education handouts.  The administration section outlined the process for 
bladder instillation therapy.   
To update the form to reflect evidence-based practice, several changes were made (see 
Appendix F).  The title was changed to Competency: Intravesicular Bladder Instillation.  
Three competency forms were developed specific to each of the three chemotherapeutic 
agents, including BCG, Mitomycin C, and Valrubicin, because each agent has a unique 
method for instilling, for patient education priorities, and for side effect profile differences.   
The first objective was changed to state the following:  RN will demonstrate safe 
handling and administration of bladder intravesical medications according to policy and 
procedure.  A third objective was added to include the following:  RN will recognize side 
effects and potential serious complications that could result in the deferment of treatment.  
These changes note the importance of prompt recognition of side effects and potential 
complications, as treatment decisions are driven by such assessments (Jones & Larchian, 
2012).   
Nursing staff currently review the article “Intravesical Antineoplastic Therapy 
Following Transurethral Resection of Bladder Tumors:  Nursing Implications for the OR to 
Discharge” prior to proceeding with orientation (Washburn, 2007).  This article is specific to 
bladder instillation therapy that is given in the OR.  Although specific to the OR, the 
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principles discussed can be applied to the ambulatory setting, and the article will therefore 
remain as part of the orientation.   
An additional article entitled “Bladder Cancer: Current Optimal Intravesical 
Treatment” has been added to the orientation program to provide additional information on 
bladder intravesical therapy (Lamm et al., 2005).  Another article was added for the nursing 
staff to review entitled, “Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG 
Treatment for Superficial Bladder Cancer” (Lukacs, Tschobotko, Szabo, & Symes, 2013).  
BCG treatment has the potential for serious complications and even death (Lukacs, 
Tschobotko, Szabo, & Symes, 2013).  It is important for the nursing staff to be knowledgeable 
regarding the potential for serious complications and this article regarding BCGosis will be 
beneficial in education related to signs and symptoms.  The nurses will also review the newly 
revised bladder instillation protocol, the hospital policy on the safe handling of hazardous 
drugs, and the Merck TICE® BCG pharmaceutical information.   
The nursing staff will review the newly updated patient education handouts regarding 
BCG, Mitomycin C, and Valrubicin, and will observe an administration of each.  The nursing 
staff will then perform three instillations while observed by experienced nursing staff who 
assess their accuracy in the use of safety equipment, procedural equipment, and 
administration.  After successfully completing the competency form, the orientees will take a 
competency quiz (see Appendix G).   
The redeveloped competency quiz will test the knowledge of the newly hired nursing 
staff to ensure that they have the knowledge to safely care for this patient population.  The 
new competency forms and the bladder instillation medication quiz have both been submitted 
to the clinic nursing educator for approval.  The changes to the nursing orientation program 
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will assist in assuring consistent care utilizing protocol for patients in the bladder instillation 
clinic. 
Discussion 
This Cancer Hospital’s mission is, “to eradicate cancer from individuals’ lives by 
creating knowledge and integrating groundbreaking research with excellence in education and 
patient centered care” (OSUMC, 2011, p. 32).  The vision of the Cancer Hospital is described 
as “Creating a cancer free world, one person, one discovery at a time” (OSUMC, 2011, p. 32).  
Bladder cancer patients are seen in the bladder instillation clinic seeking treatment for their 
superficial bladder cancer.  This project developed due to the need to improve the quality of 
care for bladder cancer patients.  These patients are entitled to receive care that is quality care 
and is consistent each time they receive their bladder intravesical therapy.  Consistent and 
standardized patient care that is evidence based is essential to the mission and goal of 
eradicating cancer and creating a cancer free world.   
This project was supported by the clinic nursing staff as well as the nurse manager and 
nursing educator for the clinic.  The nursing staff familiar with these treatments acknowledged 
the need for updated protocols and patient education materials.  The nursing staff also 
expressed a desire for an education program to increase their knowledge to allow them to 
better care for their patients.  The clinic is in the process of moving to a new location, which 
will necessitate training of newly-hired nurses who will administer intravesical therapy.  
Updating the orientation process was intended to provide better education and training to the 
newly hired nursing staff allowing for safer patient care (Lamm et al., 2005).  This DNP 
project provided important improvements to the bladder intravesical instillation clinic’s 
processes, policies, and procedures 
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Bladder Instillation Protocol 
Proposed updates to the bladder instillation protocol were successfully completed and 
are awaiting approval by nursing leadership.  In the future, the evidence-based protocol will 
provide a consistent level of care based on evidence-based practice as well as optimal patient 
outcomes (Lamers, Janisse, Brown, Butler, & Watson, 2013).  The process of updating the 
protocol initially proved to be challenging.  Upon searching for the protocol, it initially could 
not be located until a review of the chemotherapy administration protocol revealed it as a 
subgrouping of content.  In reviewing the existing protocol, it was found that there were 
multiple differences between actual practice and the existing protocol.  Care based on an 
outdated protocol had negative implications for patients as well as the organization, and in 
order to meet Joint Commission standards, revision was essential.  
The other difficulty that was encountered during the process of updating the protocol 
was the lack of more recent literature discussing the actual procedure of instilling the 
intravesical therapy.  There is a plethora of literature discussing the need for personal safety 
equipment when instilling hazardous medications.  There were articles found that discussed 
instillation of bladder intravesical medications in the operating room.  There were, however, 
no specific articles dedicated to the instillation of medication in the ambulatory setting.   
There were published protocols from other facilities for the patient undergoing bladder 
intravesical therapy.  Studies evaluating the effectiveness of BCG, Mitomycin C, and 
Valrubicin, while not specifically evaluating the protocol for instillation, did report how the 
medication was instilled, how often, and side effects noted.  The existing protocol was 
amended based on the available literature and included studies of the effectiveness of BCG in 
the OR setting as well as other healthcare facilities’ intravesicular chemotherapy protocols.   
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For these amended protocols to be enacted, it is important to have buy-in from all of 
the stakeholders utilizing the procedure.  Stakeholders are organizations, groups, or 
individuals that have a relationship with an organization and have a stake in the success of a 
project, process, or organization (Ginter, Duncan, & Swayne, 2013).  With any procedural or 
protocol change, there are a number of stakeholders that are affected.  In order to implement a 
successful change, it is important to identify the stakeholders who could be indirectly or 
directly affected.   
After the updating of the existing protocol, changes were reviewed by both nursing 
and physician staff.  There was overwhelming support for the changes to the protocol.  
Changes were made based on feedback from the nursing and physician staff to represent best 
practice.  The changes to the protocol necessitated changes to the patient education materials 
as well. 
Patient Education Material 
Updates and revisions to patient education materials should represent best practice and 
ensure that are patients receive sufficient knowledge for self care.  Education materials are 
vital to patients’ knowledge of the side effects and complications to observe for, as well as 
when to seek medical assistance after treatment.  Improving patient education can improve 
understanding of treatments and improve compliance (Kyrtatos, Constandinou, Loizides, & 
Mumtaz, 2014).  Patients reviewing the updated patient education materials stated that the 
information was easy to read and understand, and the materials are now being evaluated by 
the patient education department for approval 
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Nursing Education Program 
Improving the quality of patient care starts with nursing personnel having the 
knowledge to safely care for their patients.  Crossing the Quality Chasm focused on quality 
issues and recommended six aims – “care should be safe, effective, patient-centered, timely, 
efficient and equitable—and 10 rules for care delivery redesign” (IOM, 2013).  The DNP is in 
an excellent position to develop an education program for nursing staff to increase their 
knowledge of their bladder cancer patient population and treatment.  The nursing education 
program on February 3, 2015 accomplished that objective and was well received by attendees.   
The education program allowed for an interactive format with the nursing staff and 
faculty instructor engaging in a discussion that included case studies and questions.  The 
evaluation responses submitted after the program indicated that the content was successful in 
offering updated knowledge to improve patient care.  The nursing staff indicated that they 
would be open to attending additional education sessions in the future to continue to increase 
their knowledge.  
Nursing Orientation 
The nursing orientation process changes have been proposed to nursing leadership but 
have yet to be enacted due to…..give reader some idea of timeline or what still has to be done.  
The changes will improve the knowledge of newly hired nursing staff and apply consistent 
care to patients, thereby improving patient outcomes.  The process to change nursing 
orientation involved both nursing staff and the nursing educator for the unit.  It was important 
to make changes so that newly hired nursing staff would have the knowledge to safely care for 
patients.   
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Poor performance in the care of patients can result from nursing staff not having the 
knowledge or confidence to care for patients and poor outcomes can result (Lamers, Janisse, 
Brown, Butler, & Watson, 2013).  The current nursing staff and nursing educator reviewed the 
proposed changes and orientation check off list and approved the changes.  The changes have 
been submitted to nursing leadership for final approval.   
Conclusions 
Aspects of the bladder instillation clinic protocols, processes, and procedures have 
needed updating for the past year to reflect evidence based practice and ensure optimal patient 
outcomes.  The process of such updating was daunting at the beginning of this project.  
Having multiple areas that required updating commanded an immense amount of organization 
and commitment.  The project has been successful in updating the bladder instillation 
protocol, which is now awaiting approval by nursing leadership before it is implemented.  
Successful changes were made to update the protocol to reflect the actual practice in the clinic 
and reflect current evidence-based standards.   
A nursing education program was also successfully presented to twelve nurses.  The 
objectives of the program were to increase the nurse’s knowledge of bladder cancer, 
instillation therapy, and side effects and complications of treatment.  These objectives were 
met and the nursing evaluations were positive, indicating that the knowledge that was learned 
would be applied to patient care and basic practice.  Patient education materials were 
successfully updated to reflect the changes in the bladder instillation protocol.  Changes were 
made to nursing orientation to ensure that nursing staff has the knowledge and skill level 
needed to successfully instill bladder medications while decreasing the risk of having a 
traumatic catheter insertion or causing a urinary tract infection.  Newly-acquired articles from 
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nursing journals and other sources will now be required to better educate the nursing staff on 
bladder intravesical therapy and the medications that are being given.  
The nurses will complete a quiz at the end of orientation, as well as annually, to ensure 
competence.  Nurses will also perform three successful bladder instillations prior to being 
deemed competent to perform on their own.  The changes to the nursing orientation program 
are awaiting approval before they are implemented.  Improvements in the bladder instillation 
protocol, patient education, nursing knowledge, and orientation lead to consistent evidence 
based care and improved patient outcomes (Lamm et al., 2005). 
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Chapter V 
Project Summary 
The intravesical bladder instillation clinic in this large cancer hospital in a midwestern 
city provides care to approximately 450 patients per year.  The patients receive either BCG, 
Mitomycin C, or Valrubicin once a week for either six or three weeks depending on their 
treatment schedule for their superficial bladder cancer.  The instillation of the medication is 
performed by either the provider or the nursing staff.   
Nursing staff must be trained to instill the medication without causing trauma to the 
urethra or causing a urinary tract infection.  Side effects related to the therapy may delay 
treatment and lengthen recovery.  Standardized nursing protocols that are evidence based are 
essential to quality and safety of these patients.  Sufficient nursing knowledge about bladder 
cancer, the medications instilled as treatments, and the patient teaching required must be 
provided to outpatient nurses before they are deemed as competent to deliver such care.  
Yearly updates and evaluations must also be in place to assure that practice is standardized 
and evidence based.   
The current protocol was found to be outdated and not representative of the current 
practice or literature.  Nursing staff were wearing the correct safety equipment (listed in the 
existing protocol) to give the medication, but the protocol was inaccurate in the equipment 
that was listed.  To update the protocol a search of the literature was done, and evidence was 
reviewed from nursing journals, textbooks, and other healthcare facilities with published 
protocols.  The current protocol was revised to reflect the current urethral catheters used, the 
correct nursing safety attire, steps to the procedure, and education to be provided to the 
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patients.  The revised intravesical instillation protocol is awaiting submission to nursing 
administration for approval. 
Patient education needed to be updated as a result of the protocol changes.  The BCG 
patient education handout needed the least amount of changes as it was more recently updated 
in 2013.  The patient’s temperature was revised from 101 to 101.5 as a criterion for seeking 
treatment, and directions for where to seek treatment were revised from the emergency 
department to a medical professional.  The Mitomycin C patient handout had more extensive 
changes as it had not been updated since 2011.  Erroneous information was deleted related to 
lidocaine being instilled into the urethra and a penile clamp being applied.  Information 
regarding lying flat for fifteen minutes and then getting up to wash was added.  The 
temperature for seeking treatment was increased from 101 to 101.5 degrees Fahrenheit.   
 Valrubicin did not have any patient education information related to its 
administration, so a handout was developed utilizing the Mitomycin C template, as both 
medications are chemotherapies.  The information included was specific to Valrubicin.  The 
temperature delineation for seeing treatment was also changed to 101.5 degrees Fahrenheit for 
the Valrubicin patient information.  
Future Implications 
This DNP project has been a successful project with the changes made to improve 
quality of patient care in the bladder intravesical therapy clinic.  While positive changes have 
been made, work remains to further improve the quality of patient care.  While the protocol 
for bladder instillations has been updated, the changes have yet to be presented to nursing 
administration for review and implementation.  Due to the time constraints of this project, 
there was not enough time to prepare the documentation needed to submit the changes to 
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nursing administration for approval.  After graduation, this DNP student will therefore submit 
the changes to nursing administration for approval and implementation.  Once the necessary 
approval has been obtained, the protocol will be implemented in the clinic.  This information 
would be beneficial to other institutions.  Future publication of nursing implications and 
protocol development for bladder instillation therapy will be explored.  
Implications for Nursing Practice and the DNP Essentials 
Advanced practice nursing requires a commitment to the discipline of nursing (AACN, 
2006).  The role of the DNP is to focus on nursing practice and by translating nursing research 
into practice.  The DNP role is pivotal in effecting patient outcomes and optimizing those 
outcomes by practicing evidence based care (AACN, 2006).  As the practice doctorate in 
nursing developed, the AACN developed the eight Essentials to guide nursing practice.  This 
DNP project relates directly to several of the DNP Essentials.   
The first DNP Essential is the Essential of Scientific Underpinnings for Practice.  The 
DNP graduate needs to be translate research into practice to move the science of nursing 
forward and improve patient care.  This Essential was an integral part of this DNP project.  
This DNP project utilized the scientific process to improve the protocol for the bladder 
intravesical instillation.  Practice approaches to bladder intravesical therapy were updated to 
reflect evidence based research.  The protocol revision incorporated current evidence, 
translated research and knowledge into practice, updated practice processes, and will improve 
patient outcomes in the future.   
The second DNP Essential is Organizational and Systems Leadership for Quality 
Improvement and Systems Thinking (AACN, 2006).  Quality improvement is a process that 
guides advanced practice nurses to achieve best outcomes through best practice.  The DNP’s 
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role is to improve the quality and safety of patient care.  This DNP project was a quality 
improvement project with the objective of improving patient care.  This DNP project is in the 
process of being implemented in the bladder intravesical clinic.  The protocol revision, 
updated patient education handouts, and progressive orientation program will provide patients 
with consistent and quality care.   
The care provided by the nursing staff will be safer and improves the quality of patient 
care for patients.  Leadership is also an important component of this Essential in addition to 
quality improvement.  Leadership and teamwork skills were needed in working with nursing 
and physician team members to ensure that changes to the program were representative of the 
current evidence available.   
The sixth Essential is Interprofessional Collaboration for Improving Patient and 
Population Health Outcomes (AACN, 2006).  Collaborative efforts and an interdisciplinary 
approach were implemented to achieve and implement these program revisions.  
Communication was important in evaluating the changes needed to improve patient care.  In 
order to improve outcomes for this population, the staff of the bladder intravesical clinic 
collaborated to evaluate the proposed changes.  Feedback from the nursing staff, the nursing 
educator, and physicians was obtained prior to submission to the organization’s management 
for approval of the changes.  Teamwork increases the quality of care for all patient population.   
Essential Eight is the last Essential addressed in this DNP, which is Advanced Practice 
Nursing (AACN, 2006).  Advanced practice nursing provides leadership to nursing staff in the 
clinics.  The advanced practice nurse is in a position to share knowledge with nursing as well 
as other disciplines.  This DNP project focused, in part, on development of a nursing 
education program utilizing lecture, discussion, and a PowerPoint presentation for nursing 
BLADDER INSTILLATION THERAPY 50 
 
staff.  Nursing staff were presented with information regarding bladder cancer and treatment 
with intravesical therapy.  The plan is for nurses to implement the use of this new knowledge 
by translating it into improved quality of care and outcomes for patients. 
Conclusion 
Healthcare quality is of profound importance in hospitals, nursing facilities, and 
outpatient settings.  Medical errors can cause morbidity and mortality, with estimates of 
between 44,000 and 98,000 deaths annually related to those errors (IOM, 2009).  Many more 
patients suffer preventable injuries.  Methods to facilitate safety and quality include 
established protocols, which provide a standardized approach to procedures.  Nursing 
orientations that are updated and evidence based serve to increase nursing knowledge and 
decrease medical errors.  A consistent and standardized protocol for implementing treatments 
will facilitate patient outcomes (Bashford & Shaffer, 2012).   
This project is an important quality improvement project utilizing the Iowa model to 
improve patient care in the bladder intravesical instillation clinic at a cancer hospital 
outpatient facility. Implementation of this project has contributed to evidence-based practice 
change, high quality patient care, and optimal patient outcomes.  This DNP project improves 
patient outcomes through evidence-based practice and provides nursing staff with the training 
and knowledge to provide excellent and safe nursing care.   
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Appendix A 
NOTE:  Bold and Italicized Font highlights changes made from existing   protocol. 
  
DIVISION OF NURSING SERVICES  
  
               PATIENT CARE STANDARDS OF PRACTICE    g   
Policy    g Procedure  g  Protocol       1 Guideline                                            
  
TITLE:          BACILLUS  CALMETTE-GUERIN (BCG) and CHEMOTHERAPEUTIC AGENTS, 
ADMINISTRATION OF and CARE OF THE PATIENT RECEIVING THIS BLADDER 
INTRAVESICAL THERAPY  
  
DEFINITIONS:  
  
1) Immunotherapy - Type of biotherapy.  Mechanism of action is stimulation of immune system.  
BCG is a type of Immunotherapy. 
2) Chemotherapy:  Prevention or treatment of a disease by chemical agents.  Mitomycin C and 
Valrubicin are types of chemotherapy.    
3) Hazardous Drug:  Link to Nursing Guideline: Hazardous Drugs, Safe Handling  
Link to Pharmacy: Hazardous Drugs    
   
 POLICY STATEMENTS:  
1. Registered Nurses (RNs) who have demonstrated knowledge and skill in administration of  
BCG/Chemotherapy may administer chemotherapy/biotherapy agents.   
2. The RN administering BCG/chemotherapy agents will review the five rights of drug 
administration prior to chemotherapy /biotherapy administration.  
5 Rights:  
a) Right Patient  
b) Right Medication  
c) Right Dose  
d) Right Route  
e) Right Time  
(Mosby’s Nursing Skills lists a sixth right as being the “Right Documentation”.)  See 
statement # 6 below.  
3. The RN administering BCG/chemotherapy will practice safe handling techniques to ensure 
optimal safety for the patient and all staff that come into contact with the patient and his/her 
environment.    
4. The RN will develop an individualized teaching plan for patients receiving 
BCG/chemotherapy.  
5. The RN administering BCG/chemotherapy will review the BCG/chemotherapy administration 
procedure with the patient / family prior to administration.  
  
  
Effective Date:       07/2002    
Last Review Date: 08/2013 (amended 3/2015)  
Approval Signature on file: __________ _______   
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6. The RN will document BCG/chemotherapy administration as outlined in this policy.  
7. The RN administering BCG/chemotherapy will administer or assess the need for medications 
to prevent or minimize anticipated reactions and will monitor effectiveness to determine if 
additional symptom management is needed.    
8. NO verbal orders will be taken for BCG/chemotherapy.    
9. BCG/Chemotherapy for bladder cancer is considered a high-risk medication.  Follow 
guidelines as directed in the  “Administration of High Risk Medications” Policy.    
 
  
SUBTITLE: A. PREPARATION FOR BCG/CHEMOTHERAPY ADMINISTRATION  
  
PROCEDURAL STATEMENT:  
The RN assesses the patient’s physical and psychological readiness for BCG/chemotherapy bladder 
intravesical administration.  The RN will become familiar with the BCG/chemotherapy pharmacology: 
mechanism of action, usual dosage, route of administration, acute and long-term effects, and route of 
excretion.   
PROCEDURES:  
  
1. Prior to BCG/chemotherapy administration, the nurse should conduct a pretreatment patient          
assessment that provides data in the following areas:  
a. Past medical history relevant to planned treatment (i.e., drug allergy, cardiac, pulmonary, 
or renal disease(s), previous radiation, past surgeries, etc.).  Consider comorbidities, 
particularly with elderly patients.  
b. Previous experience with BCG/chemotherapy treatment including types of drugs 
administered, physical and emotional adverse reactions, and interventions employed 
successfully to alleviate side effects.  
c. Treatment specific, head to toe assessment including reviewing the Quantitative 
Symptom Score Sheet for hematuria and treatment side effects.  
d. Obtain and document current and accurate height and weight in stocking feet.  
e. Patient / family knowledge and learning needs relevant to regimen, desire for information, 
and motivation and readiness to learn.  Reinforce, clarify, and/or supplement information 
provided by the physician. 
f. Patient / family anxiety level related to treatment and their coping methods.  
g. Patient and / or family’s ability to manage the patient’s post treatment care in the home.  
h. Available home and community resources with referral to appropriate agencies as 
needed.  (Communicate needs to PCRM, Social Worker, CNP, or CNS as appropriate)  
            
 
2. Reviewing of treatment orders:   
  
a. Prior to administration, the nurse must review the attending physician endorsed orders.  
1) Review of Orders:  The nurse will review the orders in IHIS.  If questions arise 
when checking the BCG/chemotherapy order, the nurse should call the attending 
physician or pharmacist to seek clarification.   
a) Other resources to clarify BCG/chemotherapy orders may include:  
   
• Nurse Practitioner (NP)  
• Physician Assistant (PA)  
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b) The BCG/Chemotherapy order set should provide clear communication 
regarding:   
i. Number of doses/weeks BCG/chemotherapy is to be instilled  
ii. Time doses are to be given    
iii  Pre-medications to be given with BCG/chemotherapy  regimen (if any). 
  
  
3. BCG/Chemotherapy Checks:  
a. Prior to administering BCG/chemotherapy:   
1) Independent Double Check Procedure: Two RN’s independently compare the 
medication in hand against the order to ensure administration of the correct drug, the 
correct patient, using patient name and medical record number, at the correct dose, 
and correct rate (if applicable), given by the correct route, and at the scheduled time.  
This includes verification of current height, weight, and BSA.     
2) The RN(s) independent double checks will be documented in IHIS.    
b. At the beginning of each shift:  
1) The RN caring for the patient will verify the dose is correct and document this 
verification on the medication administration record in IHIS   
c. Missing Dose:  
1) If you are unable to locate a dose of BCG/chemotherapy and /or if you are unsure if a 
dose has been administered, then check documentation, contact pharmacist, and/or 
contact previous shift RN.   
  
OUTCOME: The patient will receive the prescribed BCG/chemotherapy in a safe and appropriate 
manner with minimal adverse reaction.  
  
SUBTITLE: B.  SAFE HANDLING OF HAZARDOUS DRUGS     
                                      
*For procedural information related to cleaning up a 
BCG/Chemotherapy spill:   
   
POLICY STATEMENTS:  
  
1. Nursing staff who administer or care for patients receiving hazardous drugs (e.g. antineoplastic and 
cytotoxic drugs) and / or investigational agents need to be knowledgeable about, and maintain safe 
handling techniques.  These techniques are designed to protect nurses and others from potential 
risks associated with exposure to hazardous drugs.  Pharmacy will determine when an 
investigational drug requires special handling and label accordingly with an  
“Antineoplastic Material, Handle Properly” or “Medication Exposure Precautions” label.            
2. Reduce the risk of contamination by prohibiting staff from eating, drinking, applying cosmetics, or 
storing foods in areas where hazardous drugs are prepared or administered.  
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INTRAVESICULAR BLADDER INSTILLATION  
  
GENERAL GUIDELINES / INFORMATION  
  
1. Used to treat bladder cancer providing direct exposure of nonmuscle invasive tumors of the 
bladder to an immunotherapeutic drug, BCG, and chemotherapeutic drugs such as thiotepa, 
mitomycin, epirubicin, doxorubicin, valrubicin, and mitoxantrone.    
2. Requires placement of a urethral catheter  
3. Nursing implications:   
a) Maintain sterile technique for catheter insertion  
b) Follow physician orders or protocol for scheduling or re-positioning the patient and leaving a Foley catheter in place after 
instilling the BCG/chemotherapy           
c) Wear appropriate PPE  
              d)   Suspect extravasation for pain not relieved with pain medication following vesicant administration.  Release the agent and urine and 
notify physician immediately   
4. Potential complications include:   
a) Urinary tract infection  
b) Cystitis  
c) Bladder contracture  
d) Urinary urgency  
e) Flu-like symptoms (following Bacillus Calmette-Guerin [BCG] administration)  
f) Potential extravasation of vesicant agents; can result in peritoneal necrosis, fistula formation, and chronic pain  
  
PROTOCOL:  
TOPIC  IMPLEMENTATION  FREQUENCY  
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List of supplies and 
equipment  
• Urethral catheter kit (without catheter)  
• Sterile gloves  
• 14 or 16 French-Coude or red rubber catheter  
• CHUX® (1)  
• Chemotherapy gloves  
• Protective plastic gown (1)   
• Medication as prepared per Pharmacist  
• Biohazard bag (Red for BCG or Yellow for 
Mitomycin/Valrubicin) 
• Exam table  
• Blanket 
• Peri-pad for patient post procedure  
  
  
Patient/Family  
Education   
Materials Available  
• Bladder Irrigation Treatment for Bladder Cancer     
• BCG Therapy – Intravesical Treatment for Bladder Cancer   
• Mitomycin – C Therapy Intravesical Treatment for Bladder 
Cancer  
• Valrubicin (Valstar) Therapy Intravesical Treatment for 
Bladder Cancer  
  
Patient Education  
  
  
1.  Explain the procedure, its risks, benefits, and after procedure 
self-care instructions.   
Before procedure  
2.  Review patient education materials (as listed above) with the 
patient.   
Before procedure  
  
TOPIC  IMPLEMENTATION  FREQUENCY  
Patient Education  
(cont.)  
3.  Explain to patient - the procedure will be done once per week 
for either three or six weeks in a row.    
  
Before procedure  
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4.  Explain to patient – maintain a normal fluid intake; do not 
force fluids before the procedure.  
  
Before procedure  
5. Explain to patient NOT to urinate for 2 hours after the 
procedure.  (BCG needs to remain in the bladder for 2 
hours but not more than 3 hours)  
Before and post 
procedure  
6. Instruct patient to VOID seated on commode for all VOIDS 
6 hours after procedure and to use same toilet every 
time.  
  
Before and post 
procedure  
  
  
7.  With the BCG treatment, have patient disinfect the voided 
urine in the toilet with an equal volume or 1 cup of household 
bleach to the urine and let it stand for 15 minutes before 
flushing the toilet twice with the toilet lid down.  This should 
be done with every void for 6 hours after the procedure.   
  
Before and post 
procedure  
8.  Instruct patient to increase fluids beginning 2 hours after 
procedure to “flush” the bladder.  
  
Before procedure  
  
9.  Encourage good hand washing technique after each void 
following procedure.  Instruct the patient to wash with 
gentle soap and water.  This medication can irritate skin on 
hands and genitals.  
  
  
  
10.  Explain possible procedure side effects and complications.  
  
Before procedure  
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11 .  Instruct patient to seek medical attention if they have a 
fever over 101.5 that does not resolve with Tylenol or 
NSAIDs after two hours or anything else they find 
bothersome.  
  
   
   
  
  
 Post procedure  
  
TOPIC  
  
IMPLEMENTATION  
  
FREQUENCY  
Procedure Specific  
Assessment  
Interventions  
  
  
  
  
  
1.  Obtain vital signs.   Before procedure  
  
2.  Assess patient for symptoms of urinary tract infection, i.e., 
temperature greater than 101.5°, chills, pain or burning with 
urination, hematuria with or without clots, urinary frequency, 
urge to urinate- but unable to urinate, cloudy or foul smelling 
urine, low back or abdominal pain, nausea/vomiting, skin rash or 
joint pain.   
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  There are three intravesical medications:  
A. Mitomycin C (chemotherapy) prepared in a 60 ml 
catheter syringe enclosed in a light sensitive bag.  
Catheter adapter will come with the syringe.  
B. Valrubicin (Valstar) (chemotherapy) prepared in a 75 ML 
infusion bag enclosed placed in a light sensitive bag.  
Tubing will come with the vial.  
C. BCG (live bacteria) in a vial with a rubber stopper placed 
in a light sensitive bag.  Tubing will come with the vial.  
   
5.  Obtain and set up equipment / supplies for the procedure.   
   
6.  Have patient remove clothing from the waist down.  Have 
patient sit on a protective plastic barrier on the table and 
cover with a blanket.  Assist patient to a supine position prior 
to procedure.   
7.  Obtain physician order for Lidocaine 2% Uro-Jet, if 
indicated, and instill into urethra prior to catheterization.   
Before procedure  
8.  Insert 14 or 16 Coude or red rubber catheter. Allow urine to 
drain into sterile container and discard contents.  Verify non-
traumatic catheterization by return of clear yellow urine.  
During procedure   
9.  PPE (mask, goggles, gloves (chemo and sterile), and fluid 
resistant gown) will be worn from start to finish of procedure.   
Entire procedure  
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TOPIC  
  
IMPLEMENTATION  
  
FREQUENCY  
Procedure Specific  
Assessment  
Interventions  
(cont.)  
10.  Medication Installation (Physician, Certified Nursing 
Practitioner, Physician Assistant and/or RN)  
  
A. Mitomycin C:  The medicine comes prepared in a 60 ml 
toomey syringe.  Insert urethral catheter in patient. 
Instill medicine into urethral catheter by slow injecting 
the medication into the bladder.  Remove the ureteral 
catheter.  Place all items exposed to medicine in a 
yellow biohazard bag.  Place bag in yellow chemo 
waste container.  
B. BCG:  Medicine comes from pharmacy in a vial with a 
rubber stopper with special tubing for access (BCG 
Instillation Set).  Attach pointed end of tubing into 
rubber stopper.  Attach other end of tubing into end of 
urethral catheter.  Hold the vial of BCG upside down 
and squeeze the bottle to start the flow of medication 
down the tubing.  Allow medicine to drain into bladder 
by gravity.  Remove the urethral catheter.  Place all 
items exposed to medicine in a red biohazard bag.  
Place bag in a red biohazard waste container. 
C. Valrubicin: The medicine comes prepared in a 75 ml 
instillation bag.  Insert urethral catheter in patient. 
Instill medicine into urethral catheter by slowly 
releasing the clamp to allow the medication to instill by 
gravity into the bladder.  Remove the urethral catheter. 
Place all items exposed to medicine in a yellow 
biohazard bag.  Place bag in yellow chemo waste 
container.  
    
 
During procedure  
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11. Patient should not void for 2 hours post procedure.   
  
Post Procedure  
  
Post Procedure  
Complications  
Signs/Symptoms  
  
1. Have patient watch for any signs and symptoms of 
infection, such as fever, chills, malaise, and flu-like 
symptoms.  Notify physician if fever greater than 101.5° 
and does not resolve after 2 hours with Tylenol or NSAIDs, 
or go to the nearest Emergency Room.  
2. It is normal to have burning with urination, urinary 
frequency, and urinary urgency after the procedure.  Note 
any burning with urination that persists beyond three to 
five days post procedure.   
  
  
Post procedure  
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Appendix B 
NOTE:  Bold and italicized font notes changes made from existing handout.. 
PATIENT EDUCATION 
 
BCG Therapy - Intravesical Treatment for 
Bladder Cancer 
 
 Your doctor has recommended that you be treated with Bacillus Calmette-Guerin (BCG) Therapy.  BCG is an 
intravesical therapy. Intravesical is when a liquid treatment is placed into the bladder through a catheter or tube. 
BCG is the best treatment for your type of bladder cancer.  It is a live Tuberculosis (TB) vaccine which has been 
weakened to reduce the risk of infection.  This will help your body’s immune system to fight the cancer cells.  BCG 
lowers the chance that cancer will return or continue to grow.  This treatment is well tolerated and is safe.  This 
treatment is usually given once a week for six weeks.  Alternately, it can be given once a week for three weeks if 
receiving maintenance therapy. 
Before Your Treatment 
• Do not drink anything for 4 hours before treatment.   
• Empty your bladder right before the treatment.  
• You will be given a form called, the Quantitative Symptom Score Sheet.  
• On the day of your first treatment, you will fill in the Pre-Treatment column on the form. Your nurse will help 
you fill out this information.  
• Bring your Quantitative Symptom Score Sheet with you to each visit.  Make sure to fill it out around the same 
time each day. Your nurse will discuss your answers with you before your treatment.  
On the Day of Your Treatment 
• You will be asked to undress from the waist down and given a sheet to cover yourself.  
 
This handout is for informational purposes only.  Talk with your doctor or health care team if you 
have any questions about your care. 
© March 13, 2015.   
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• Your nurse will have you lie on your back on the exam table.  
• A cleansing solution called Betadine will be used to lower the risk of infection from the catheter placement. 
• Lidocaine gel, a numbing medicine, will be placed into your urethra to make the catheter placement more 
comfortable.  The urethra is the tube that carries urine out of your body.  
• The catheter will be placed into your urethra.  
• This catheter will let the urine drain from the bladder.  Once the urine is drained, BCG will be placed into your 
bladder through the same catheter.  
• After the BCG is given, the catheter is removed.  The BCG will remain in your bladder.  You will need to lie 
flat for 15 minutes after the procedure. 
• After lying flat, you will then be able to get dressed.  You will need to wear a pad home to soak up any liquid 
that may leak out.   
After Your Treatment 
• Do not drink anything for 2 hours after your treatment.  
• To keep the BCG in your bladder, do not urinate for 2 hours if possible.  However, do not hold your urine for 
longer than 3 hours.  
• Write down how long you held the medicine in your bladder on the bottom of your Quantitative Symptom 
Score Sheet.  Your nurse will ask you for this information at each visit.  You may return to your normal 
activities. 
Safety Precautions  
• Use the same toilet in your home each time you urinate.  
• To avoid splashing or spraying, sit on the toilet while you urinate.  
• During the first 6 hours after treatment, follow these steps each time you urinate:  
  Do not flush the toilet when you finish urinating.  
  Before you flush, you must first pour 1 cup of bleach into the toilet, and let it sit for 15 minutes.  You 
should then close the lid and flush the toilet two times.   
BCG Therapy - Intravesical Treatment for Bladder Cancer 
  Wash your hands and genital area with soap and water after each time you urinate to avoid skin irritation.  
  Any clothes or linens that have urine on them should be washed on the hot cycle in a washing machine.  
Wash soiled laundry separately. 
  If urine splashes or spills on the floor, toilet seat or other areas clean it up with a water and bleach mixture 
(1/2 cup bleach and 4 cups of water). 
• If you are sexually active you or your partner must wear a condom: 
  During your 6 weeks of treatment  
  And for 1 week after your last treatment 
Side Effects 
These symptoms usually do not last longer than 3 to 5 days.  There are medicines that can reduce side effects.  Tell 
your doctor or nurse if you have any of the following:  
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• Fever  
• Frequent urination 
• Urgency of urination 
• Blood in urine 
• Burning while urinating 
• Bladder spasms or pain 
• Arthritic or joint pain 
• Flu-like symptoms 
If you have a temperature greater than 101.5 degrees Fahrenheit that does not resolve within two hours after 
taking Tylenol or Ibuprofen, seek medical attention.  
 
BCG Therapy - Intravesical Treatment for Bladder Cancer 
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Appendix C 
 
NOTE:  Bold and italicized font notes changes made from existing handout. 
 
PATIENT EDUCATION 
 
Mitomycin-C Therapy Intravesical  
Treatment for Bladder Cancer 
 
Your doctor has recommended that you be treated with Mitomycin-C therapy.  Mitomycin-C is an intravesical 
therapy. Intravesical is when a liquid treatment is placed into the bladder through a catheter or tube. 
Mitomycin-C is the best treatment for your type of bladder cancer.  
It lowers the chance that the cancer will return or continue to grow.  Mitomycin-C is a chemotherapy drug.  
However, because it is given through the bladder, it does not usually have the same side effects as chemotherapy 
given through an IV.  This treatment is well tolerated and is safe.  This treatment is usually given once a week for 
six weeks. 
Before Your Treatment 
• Do not drink anything for 4 hours before treatment.   
• Empty your bladder right before the treatment.  
• You will be given a form, called the Quantitative Symptom Score Sheet.  
• On the day of your first treatment, you will fill in the Pre-Treatment column on the form.  Your nurse will help 
you fill out this information.  
• Bring your Quantitative Symptom Score Sheet with you to each visit.  Make sure to fill it out around the same 
time each day. Your nurse will discuss your answers with you before your treatment.  
On the Day of Your Treatment 
• You will be asked to undress from the waist down and given a sheet to cover yourself.  
• Your nurse will have you lie on your back on the exam table.  
 
This handout is for informational purposes only.  Talk with your doctor or health care team if you 
have any questions about your care. 
© March 13, 2015.     
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• A cleansing solution called Betadine will be used to lower the risk of infection from the catheter placement. 
• Lidocaine gel, a numbing medicine, will be placed into your urethra to make the catheter placement more 
comfortable. The urethra is the tube that carries urine out of your body.  
• The catheter will be placed into your urethra.  
• This catheter will let the urine drain from the bladder.  Once the urine is drained, Mitomycin-C will be placed 
into your bladder through the same catheter.  
• After the Mitomycin-C is given, the catheter is removed.  The Mitomycin-C will remain in the bladder.  You 
will need to lie flat for 15 minutes after the procedure.  After lying flat for 15 minutes, you will be able to get 
up, wash your genital area, and get dressed.  You will need to wear a pad home to soak up any liquid that 
may leak out.   
After Your Treatment 
• Do not drink anything for 2 hours after your treatment.  
• Try to keep the Mitomycin-C in your bladder and do not urinate for 2 hours if possible.  However, do not 
hold your urine for longer than 3 hours.  
• Write down how long you held the medicine in your bladder on your Quantitative Symptom Score Sheet.  
Your nurse will ask you for this information at each visit. 
• You may return to your normal activities. 
Safety Guidelines 
• Use the same toilet in your home each time you urinate.  
• To avoid splashing or spraying, sit on the toilet while you urinate.  
• During the first 6 hours after treatment, follow these steps each time you urinate:  
  After urinating, flush the toilet twice with the toilet lid down.  
  Wash your genital area after you urinate to avoid skin irritation.  
• If you are sexually active you or your partner must wear a condom: 
  During your 6 weeks of treatment  
  And for 1 week after your last treatment 
Side Effects 
These symptoms usually do not last longer than 3 to 5 days.  There are medicines that can reduce side effects.  Tell 
your doctor or nurse if you have any of the following:  
• Fever  
• Frequent urination 
• Urgency of urination 
• Blood in urine 
• Burning while urinating 
• Bladder spasms or pain 
If you have a temperature greater than 101.5 degrees Fahrenheit that does not resolve within two hours after 
taking Tylenol or Ibuprofen, seek medical attention.  
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Appendix D 
 
NOTE:  This is a newly developed patient education handout.  
 
PATIENT EDUCATION 
 
Valrubicin (Valstar) Therapy Intravesical  
Treatment for Bladder Cancer 
 
Your doctor has recommended that you be treated with Valrubicin therapy.  Valrubicin is an intravesical therapy.  
Intravesical is when a liquid treatment is placed into the bladder through a catheter or tube. 
Valrubicin is the best treatment for your type of bladder cancer.  
It lowers the chance that the cancer will return or continue to grow.  Valrubicin is a chemotherapy drug.  However, 
because it is given through the bladder, it does not usually have the same side effects as chemotherapy given through 
an IV.  This treatment is well tolerated and is safe.  This treatment is usually given once a week for six weeks. 
Before Your Treatment 
• Do not drink anything for 4 hours before treatment.   
• Empty your bladder right before the treatment.  
• You will be given a form, called the Quantitative Symptom Score Sheet.  
• On the day of your first treatment, you will fill in the Pre-Treatment column on the form.  Your nurse will help 
you fill out this information.  
• Bring your Quantitative Symptom Score Sheet with you to each visit.  Make sure to fill it out around the same 
time each day. Your nurse will discuss your answers with you before your treatment.  
On the Day of Your Treatment 
• You will be asked to undress from the waist down and given a sheet to cover yourself.  
• Your nurse will have you lie on your back on the exam table.  
 
This handout is for informational purposes only.  Talk with your doctor or health care team if you 
have any questions about your care. 
© March 13, 2015.     
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• A cleansing solution called Betadine will be used to lower the risk of infection from the catheter placement. 
• Lidocaine gel, a numbing medicine, will be placed into your urethra to make the catheter placement more 
comfortable. The urethra is the tube that carries urine out of your body.  
• The catheter will be placed into your urethra.  
• This catheter will let the urine drain from the bladder.  Once the urine is drained, Valrubicin will be placed into 
your bladder through the same catheter.  
• After the Valrubicin is given, the catheter is removed.  The Valrubicin will remain in the bladder.  You will 
need to lie flat for 15 minutes after the procedure.  After lying flat for 15 minutes, you will be able to get up, 
wash your genital area, and get dressed.  You will need to wear a pad home to soak up any liquid that may leak 
out.   
After Your Treatment 
• Do not drink anything for 2 hours after your treatment.  
• Try to keep the Valrubicin in your bladder; do not urinate for 2 hours if possible.  However, do not hold your 
urine for longer than 3 hours.  
• Write down how long you held the medicine in your bladder on your Quantitative Symptom Score Sheet.  Your 
nurse will ask you for this information at each visit. 
• You may return to your normal activities. 
Safety Guidelines 
• Use the same toilet in your home each time you urinate.  
• To avoid splashing or spraying, sit on the toilet while you urinate.  
• During the first 6 hours after treatment, follow these steps each time you urinate:  
  After urinating, flush the toilet twice with the toilet lid down.  
  Wash your genital area after you urinate to avoid skin irritation.  
• If you are sexually active you or your partner must wear a condom: 
  During your 6 weeks of treatment  
  And for 1 week after your last treatment 
Side Effects 
These symptoms usually do not last longer than 3 to 5 days.  There are medicines that can reduce side effects. Tell 
your doctor or nurse if you have any of the following: Fever  
• Frequent urination 
• Urgency of urination 
• Blood in urine 
• Burning while urinating 
• Bladder spasms or pain 
 
If you have a temperature greater than 101.5 degrees Fahrenheit that does not resolve within two hours after 
taking Tylenol or Ibuprofen, seek medical attention.  
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Appendix E 
 
Hospital Division of Nursing 
Competency: Intravesical Bladder Therapy Administration 
 
Name______________________         Date_______________ 
Objectives 
1. RN will demonstrate safe handling and administration of bladder intravesical medications according to policy and procedure. 
2. RN will describe patient education process, resources, and documentation.  
3. RN will recognize side effects and potential serious complications that could result in deferment of treatment. 
 
 
Components Evaluation Date Evaluator Signature 
Participant Signature (if self 
study) 
• Review 
1. James Policy:  
Chemotherapeutic & Biotherapeutic Agents, 
Administration of and Care of the Patient 
Receiving this Therapy 
2. James policy:  Hazardous Drugs, Safe 
Handling 
3. TICE BCG pharmaceutical drug insert 
(Merck, 2013) 
4. Literature:  Bladder Cancer: Current Optimal 
5. Intravesical Treatment (Lamm, McGee, Hale, 
2005) 
6. Systemic BCG-Osis as a Rare Side Effect of 
Intravesical BCG Treatment for Superficial 
Bladder Cancer (Lukacs, Tschobotko, Szabo, 
& Symes, 2013) 
 
Yes         No 
  
• Patient Education 
1. Review James Patient Education: BCG 
 
Yes         No 
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Therapy – Intravesical Treatment for Bladder 
Cancer, Mitomycin-C Therapy Intravesical 
Treatment for Bladder Cancer, and Valrubicin 
Therapy for Bladder Cancer  
2. Describes appropriate patient education, 
resources, and EMR documentation 
 
 
 
Met        Unmet 
• Complete written case study with score of at least 
80% 
Yes         No 
 
  
• Administration 
1. Verbalizes parameters to evaluate prior to 
administration 
2. Verbalizes correct management of side effects 
and complications 
3. Demonstrates intravascular bladder therapy 
administration according to policy and 
procedure 
4. Describes appropriate documentation of 
procedure. 
 
Met        Unmet 
 
 
Met        Unmet 
 
 
Met        Unmet 
 
 
Met        Unmet 
  
Resources used to develop education:  James Policy:  Chemotherapeutic & Biotherapeutic Agents, Administration of and 
Care of the Patient Receiving this Therapy & Hazardous Drugs, Safe Handling, TICE BCG pharmaceutical drug insert 
(Merck, 2009), Nursing Implications from the OR to Discharge (Washburn, 2007), Systemic BCG-Osis as a Rare Side 
Effect of Intravesical BCG Treatment for Superficial Bladder Cancer (Lukacs, Tschobotko, Szabo, & Symes, 2013), 
James Patient Education: BCG Therapy – Intravesical Treatment for Bladder Cancer, Mitomycin-C Therapy Intravesical 
Treatment for Bladder Cancer, and Valrubicin Therapy for Bladder Cancer 
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Hospital Division of Nursing 
Competency: Intravesical Bladder Therapy Administration 
BCG Competence Checklist 
 
 
Skill:  Intravesical Bladder Therapy Administration:  BCG 
 
Name_________________________                                                                                        Date____________ 
 
 
Critical Elements Met Not 
Met 
N/A Comments 
Completed written quiz 
with a grade of at least 
80%. 
    
Verbalizes parameters to 
evaluate prior to BCG 
administration 
    
Observes three BCG 
bladder instillations 
    
Demonstrates three 
intravesical BCG bladder 
instillations according to 
policy and procedure 
    
Verbalizes correct 
management of BCG 
side effects and 
complications 
    
 
□  Satisfactory       □  Unsatisfactory  
Name and Title of Evaluator_________________________________________________      
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Hospital Division of Nursing 
Competency: Intravesical Bladder Therapy Administration 
Mitomycin C Competence Checklist 
 
 
Skill:  Intravesical Bladder Therapy Administration:  Mitomycin C (MMC) 
 
Name_________________________                                                                                        Date____________ 
 
 
Critical Elements Met Not 
Met 
N/A Comments 
Completed written quiz 
with a grade of at least 
80%. 
    
Verbalizes parameters to 
evaluate prior to MMC 
administration 
    
Observes three MMC 
bladder instillations 
    
Demonstrates three 
intravesical MMC 
bladder instillations 
according to policy and 
procedure 
    
Verbalizes correct 
management of MMC 
side effects and 
complications 
    
 
□  Satisfactory       □  Unsatisfactory  
Name and Title of Evaluator_________________________________________________      
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Hospital Division of Nursing 
Competency: Intravesical Bladder Therapy Administration 
Valrubicin Competence Checklist 
 
Skill:  Intravesical Bladder Therapy Administration:  Valrubicin (Valstar) 
 
Name_________________________                                                                                        Date____________ 
 
Critical Elements Met Not 
Met 
N/A Comments 
Completed written quiz 
with a grade of at least 
80%. 
    
Verbalizes parameters to 
evaluate prior to Valstar 
administration 
    
Observes three Valstar 
bladder instillations 
    
Demonstrates three 
intravesical Valstar 
bladder instillations 
according to policy and 
procedure 
    
Verbalizes correct 
management of Valstar 
side effects and 
complications 
    
□  Satisfactory       □  Unsatisfactory  
Name and Title of Evaluator_________________________________________________  
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Appendix F 
Intravesical Bladder Therapy Administration Quiz 
 
 
Name_________________________                                           Date_______________ 
 
1. What are the three types of intravesical medications used in the BCG clinic for superficial 
bladder cancer? 
a. __________________________________________________________ 
b. __________________________________________________________ 
c. __________________________________________________________ 
 
2. What are the most common size and types of urethral catheters used for instilling 
intravesical bladder medications into a male and female patient’s bladders? 
a. __________________________________________________________ 
b. __________________________________________________________ 
 
3. A patient presents to the clinic for his bladder instillation therapy.  He is complaining of 
severe dysuria, increased urinary frequency and urgency, and hematuria since his last 
treatment.  The nurse will discuss the symptoms with the provider but orders the BCG 
from pharmacy knowing that treatment will probably proceed as scheduled.  
a. True or False 
 
4. Upon inserting the urethral catheter into the bladder, the nurse notices there is a moderate 
amount of hematuria.  What is the nurse’s next step? 
___________________________________________________________________ 
___________________________________________________________________ 
___________________________________________________________________ 
 
5. The nurse is educating a new patient on side effects that they may experience.  What 
temperature should the patient be counseled to seek medical attention or call their 
provider for?  
____________________________________________________________________ 
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6. Name two side effects a patient may experience as a result of bladder intravesical 
therapy. 
a. ______________________________________________________________ 
b. _______________________________________________________________ 
 
7. BCGosis can be a life threatening complication of BCG instillation therapy.  What causes 
BCGosis? 
            _________________________________________________________________ 
8. List three symptoms of BCGosis. 
a. _________________________________________________________________ 
b. _________________________________________________________________ 
c. _________________________________________________________________ 
 
9. How long should a patient be instructed to hold the intravesical medication in his/her 
bladder? 
a. _________________________________________________________________ 
 
10.  What safety equipment should a nurse wear to protect themselves from exposure to 
biohazardous medications such as BCG, Mitomycin C and Valrubicin? 
a. __________________________________________________________________ 
b. __________________________________________________________________ 
c. __________________________________________________________________ 
d. __________________________________________________________________ 
 
11.  Would the nurse educate the patient to expect possible flu like symptoms of fever and 
body aches with Mitomycin C instillation therapy? 
a. True or False? 
 
12. What are two Irritative voiding side effects a patient may experience when receiving 
Mitomycin C or Valrubicin intravesical instillation therapy? 
a. __________________________________________________________________ 
b. __________________________________________________________________ 
 
13. BCG can be given in either an induction course or a maintenance course.  How many 
doses does a patient receive with each treatment? 
a. __________________________________________________________________ 
b. __________________________________________________________________ 
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14. What is the standard dose used at the James for BCG, MMC, and Valrubicin? 
a. __________________________________________________________________ 
b. __________________________________________________________________ 
c. __________________________________________________________________ 
 
15. Holding intravesical bladder instillation medication longer than two to three hours will 
not increase a patient’s side effects. 
a. True or False 
 
 
 
 
 
 
            
 
 
